Evelo Biosciences(EVLO) - 2022 Q4 - Earnings Call Transcript

Shamira Shariffudin - Director Business Development Conference Call Participants Peyton Bohnsack - Cowen Shamira Shariffudin Simba Gill Beyond progress on our EV program, I wanted to recap a few highlights from last year. In late 2021, we reported that our Phase 2 mild to moderate psoriasis study on EDP1815 significantly [indiscernible] versus placebo at the end of the 16-week treatment period. PASI-50 or greater responses were 25% to 32% versus 12% for placebo with statistical significance of P value less ...